Citation: Haichao Zhu, Meihua Liu, Haiyan Li, Ting Guan, Qi Zhang, Yang Chen, Yingxiang Liu, Rolf R. Hartmann, Lina Yin, Qingzhong Hu. Design, synthesis and biological evaluation of pyridyl substituted benzoxazepinones as potent and selective inhibitors of aldosterone synthase[J]. Chinese Chemical Letters, ;2021, 32(7): 2327-2332. doi: 10.1016/j.cclet.2020.11.021 shu

Design, synthesis and biological evaluation of pyridyl substituted benzoxazepinones as potent and selective inhibitors of aldosterone synthase

Haichao Zhu ^{a, 1} ,
Meihua Liu ^{a, 1} ,
Haiyan Li ^a ,
Ting Guan ^a ,
Qi Zhang ^a ,
Yang Chen ^a ,
Yingxiang Liu ^a ,
Rolf R. Hartmann ^b ,
Lina Yin ^{a, *,} ,
Qingzhong Hu ^{a, *,}

a.
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 51006, China
b.
Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, D-66123, Saarbrücken, Germany

linayin@gzucm.edu.cn

huqqzh@gzucm.edu.cn

Received Date: 30 August 2020
Revised Date: 2 October 2020
Accepted Date: 10 November 2020
Available Online: 10 November 2020

Figures(3)

Exorbitant aldosterone is closely associated with various severe diseases, including congestive heart failure and chronic kidney disease. As aldosterone synthase is the pivotal enzyme in aldosterone biosynthesis, its inhibition constitutes a promising treatment for these diseases. Via a structure-based approach, a series of pyridyl substituted 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-ones were designed as inhibitors of aldosterone synthase. Six compounds (5j, 5l, 5m 5w, 5x and 5y) distinguished themselves with potent inhibition (IC₅₀ < 100 nmol/L) and high selectivity over homogenous 11β-hydroxylase. As the most promising compound, 5x exhibited an IC₅₀ of 12 nmol/L and an excellent selectivity factor (SF) of 157, which are both superior to those of the reference fadrazole (IC₅₀=21 nmol/L, SF=7). Importantly, 5x showed no inhibition against steroidogenic CYP17, CYP19 and a panel of hepatic CYP enzymes indicating an outstanding safety profile. As it manifested satisfactory pharmacokinetic properties in rats, compound 5x was considered as a drug candidate for further development.
- Aldosterone synthase,
- Selective inhibitors,
- Benzoxazepinones,
- Heart failure,
- Renal diseases
1. [1]
  J.M. Luther, Curr. Opin. Nephrol. Hypertens. 25 (2016) 16-21. doi: 10.1097/MNH.0000000000000189
2. [2]
  A. Cannavo, A. Elia, D. Liccardo, G. Rengo, W.J. Koch, Vitam. Horm. 109 (2019) 387-406. doi: 10.1016/bs.vh.2018.09.005
3. [3]
  A. Shrestha, R.C. Che, A.H. Zhang, Adv. Exp. Med. Biol. 1165 (2019) 325-346. doi: 10.1007/978-981-13-8871-2_15
4. [4]
  F. Zannad, W. Gattis Stough, P. Rossignol, et al., Eur. Heart J. 33 (2012) 2782-2795. doi: 10.1093/eurheartj/ehs257
5. [5]
  N. Wan, A. Rahman, A. Nishiyama, J. Hum. Hypertens. 35 (2021) 148–156. doi: 10.1038/s41371-020-0377-6
6. [6]
  R. Gros, Q. Ding, L.A. Sklar, et al., Hypertension 57 (2011) 442-451. doi: 10.1161/HYPERTENSIONAHA.110.161653
7. [7]
  M. Packer, Circulation 137 (2018) 1614-1631. doi: 10.1161/circulationaha.117.032474
8. [8]
  Q. Hu, L. Yin, R.W. Hartmann, J. Med. Chem. 57 (2014) 5011-5022. doi: 10.1021/jm401430e
9. [9]
  M. Voets, I. Antes, C. Scherer, et al., J. Med. Chem. 48 (2005) 6632-6642. doi: 10.1021/jm0503704
10. [10]
  L. Yin, Q. Hu, J. Emmerich, et al., J. Med. Chem. 57 (2014) 5179-5189. doi: 10.1021/jm500140c
11. [11]
  Q. Hu, L. Yin, A. Ali, et al., J. Med. Chem. 58 (2015) 2530-2537. doi: 10.1021/acs.jmedchem.5b00079
12. [12]
  N. Strushkevich, A.A. Gilep, L. Shen, et al., Mol. Endocrinol. 27 (2013) 315-324. doi: 10.1210/me.2012-1287
1. [1]
  Yue Xu , Lingzhi Wang , Liu Yang , Renliang Xue , Haowen Zhu , Qifeng Liu , Xueqi Lv , Ruiping Zhang , Jun Tu , Qingce Zang , Yinghong Wang . Spatial metabolomics combined with transcriptomics to reveal heterogeneous metabolism and drug response in the heart of rats with heart failure. Chinese Chemical Letters, 2025, 36(7): 110958-. doi: 10.1016/j.cclet.2025.110958
2. [2]
  Deyan Wu , Qingjiang Ma , Yanquan Chen , Guofeng Yang , Fengcai Zhang , Meiyan Jiang , Xue Wang , Xingfu Liu , Qian Zhou , Yi-You Huang , Zhe Li , Hai-Bin Luo . Plasma metabolites-based drug design: Discovery of novel and highly selective phosphodiesterase 5 inhibitors. Chinese Chemical Letters, 2026, 37(5): 111236-. doi: 10.1016/j.cclet.2025.111236
3. [3]
  Han Yuan , Fengcai Zhang , Hongzhe Huang , Jiafei Wu , Yi Yang , Wanyi Huang , Dongjing Yang , Zhuoming Li , Zhe Li , Ling Huang , Yi-You Huang , Hai-Bin Luo , Lei Guo . Discovery of 3-trifluoromethyl-substituted pyrazoles as selective phosphodiesterase 10A inhibitors for orally attenuating isoprenaline-induced cardiac hypertrophy. Chinese Chemical Letters, 2025, 36(4): 109965-. doi: 10.1016/j.cclet.2024.109965
4. [4]
  Yuanyi Zhou , Lili Wang , Li Chen , Qingbing Zha , Yu Meng , Mingshan Zhu . Functional inorganic nanomaterials for renal cell carcinoma treatment: Advancements and trends. Chinese Chemical Letters, 2025, 36(12): 110994-. doi: 10.1016/j.cclet.2025.110994
5. [5]
  Botao Yan , Hongran Chen , Zixin Deng , Mingguo Jiang , Min Xu , Anwei Hou . Functional analysis of a diterpene synthase for jiangxidienes and jiangxienols biosynthesis from Streptacidiphilus jiangxiensis. Chinese Chemical Letters, 2026, 37(9): 112790-. doi: 10.1016/j.cclet.2026.112790
6. [6]
  Li Li , Jiale Wen , Xiaojun Zhang , Shuwen Fu , Zixuan Chen , Kai Huang , Luyue Fang , Tinghe Zhao , Peipei Zhang , Xingshu Li . A near-infrared naphthalocyanine photosensitizer with superior light absorption and renal clearance for type-Ⅰ photodynamic and photothermal combination therapy. Chinese Chemical Letters, 2025, 36(6): 110290-. doi: 10.1016/j.cclet.2024.110290
7. [7]
  Pan Luo , Jian-Ming Lv , Hong-Ting Zhen , Ying-Qi Zhao , Jing-Yuan Liu , Jin-Yu Hong , Shao-Yang Li , Gao-Qian Wang , Guo-Dong Chen , Shui-Xing Zhang , Dan Hu , Hao Gao . Identification of two novel sesterterpene skeletons offers the first experimental evidence for the cyclization mechanism of mangicdiene synthase. Chinese Chemical Letters, 2026, 37(1): 111042-. doi: 10.1016/j.cclet.2025.111042
8. [8]
  Jing Guo , Zhi-Guo Lu , Rui-Chen Zhao , Bao-Ku Li , Xin Zhang . Nucleic acid therapy for metabolic-related diseases. Chinese Chemical Letters, 2025, 36(3): 109875-. doi: 10.1016/j.cclet.2024.109875
9. [9]
  Dayang Xie , Qiannan Cao , Huapan Fang , Yanhui Li , Huayu Tian . Applications and challenges of biomedical polymer materials in pulmonary diseases. Chinese Chemical Letters, 2026, 37(2): 111032-. doi: 10.1016/j.cclet.2025.111032
10. [10]
  Xiaodan Liang , Tong Tong , Caihong Xian , Jiyuan Du , Biying Tan , Liying Wang , Jingyi Hou , Jun Wu . Metal-based biomaterials for treating bone diseases. Chinese Chemical Letters, 2026, 37(4): 111140-. doi: 10.1016/j.cclet.2025.111140
11. [11]
  Dongfan Li , Jinlong Lv , Jian-Cang Wang , Jiaxiang Liu , Huizhe Niu , Lu Yang , Hao Luo , Du Lv , Lichun Niu , Zemin He , Zongcheng Miao . Interface challenges of solid-state electrolytes/lithium metal anode: From origin analysis, failure mechanism to interface optimization strategies. Chinese Chemical Letters, 2026, 37(3): 111905-. doi: 10.1016/j.cclet.2025.111905
12. [12]
  Lian Jin , Juan Zhang , Libo Nie , Yan Deng , Ghulam Jilany Khana , Nongyue He . Chitosan nanoparticles act as promising carriers of microRNAs to brain cells in neurodegenerative diseases. Chinese Chemical Letters, 2025, 36(10): 110774-. doi: 10.1016/j.cclet.2024.110774
13. [13]
  Mengdie Li , Shundong Cai , Hongjin Li , Yuhang Cheng , Jinfa Ye , Lang Ke , Yun Han , Min Su , Gang Liu , Chengchao Chu . Nanotherapeutics for ocular posterior segment diseases therapy: Towards its advances and challenges. Chinese Chemical Letters, 2026, 37(5): 111392-. doi: 10.1016/j.cclet.2025.111392
14. [14]
  Jiahao Huang , Yongfeng Lan , Lifa Chen , Xiaoxuan Guan , Rong Liang , Jiatong Liang , Ming Gao , Jialiang Gan , Yun Guo , Sen Zhang . Living therapeutics: Colorectal related diseases precision therapy with engineered organisms. Chinese Chemical Letters, 2026, 37(6): 112151-. doi: 10.1016/j.cclet.2025.112151
15. [15]
  Kaiqing Zhang , Yue Zhou , Guanlin Wang , Bing Zhu , Ziyu Zhao , Xi Kong , Yihong Gao , Xin Pan , Zhengwei Huang , Chuanbin Wu , Xuejuan Zhang . Pulmonary mRNA delivery systems for the treatment of respiratory diseases: Current advances and challenges. Chinese Chemical Letters, 2026, 37(8): 111887-. doi: 10.1016/j.cclet.2025.111887
16. [16]
  Yuke Ji , Jia Liang , Xiangqing Hei , Lu Chen , Shudong Yu , Dong Fang , Hui Tan , Shaochong Zhang . Nanomaterial-based drug delivery systems for ocular diseases: A review. Chinese Chemical Letters, 2026, 37(9): 112062-. doi: 10.1016/j.cclet.2025.112062
17. [17]
  Yaling Wei , Jiaming He , Jinsong Ding , Caiyang Lu , Wenhu Zhou , Xinjie Deng . Zinc for skin diseases treatment: Progress and prospects in advanced delivery systems. Chinese Chemical Letters, 2026, 37(10): 112425-. doi: 10.1016/j.cclet.2026.112425
18. [18]
  Wenfeng Shao , Chuanlin Li , Chenggang Wang , Guangsen Du , Shunshun Zhao , Guangmeng Qu , Yupeng Xing , Tianshuo Guo , Hongfei Li , Xijin Xu . Stabilization of zinc anode by trace organic corrosion inhibitors for long lifespan. Chinese Chemical Letters, 2025, 36(3): 109531-. doi: 10.1016/j.cclet.2024.109531
19. [19]
  Lu-Lu He , Lan-Tu Xiong , Xin Wang , Yu-Zhen Li , Jia-Bao Li , Yu Shi , Xin Deng , Zi-Ning Cui . Application of inhibitors targeting the type III secretion system in phytopathogenic bacteria. Chinese Chemical Letters, 2025, 36(4): 110044-. doi: 10.1016/j.cclet.2024.110044
20. [20]
  Muhammad Nafees , Muhammad Hanif , Piaoping Yang . Metallodrugs: From mere cytotoxic agents to immune modulators and checkpoint inhibitors. Chinese Chemical Letters, 2026, 37(4): 111013-. doi: 10.1016/j.cclet.2025.111013

Get Citation

PDF

XML

Metrics

PDF Downloads(12)
Abstract views(2365)
HTML views(240)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142